Patents by Inventor Muller Fabbri

Muller Fabbri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170002353
    Abstract: The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Toll-like receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.
    Type: Application
    Filed: August 29, 2016
    Publication date: January 5, 2017
    Applicant: Ohio State Innovation Foundation
    Inventors: Carlo M. Croce, Muller Fabbri
  • Patent number: 9481885
    Abstract: The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Tolllike receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 1, 2016
    Assignee: Ohio State Innovation Foundation
    Inventors: Carlo M. Croce, Muller Fabbri
  • Publication number: 20160243192
    Abstract: Described herein are methods, pharmaceutical compositions and kits for treating cancer in a subject in need thereof by administering an effective amount of a composition comprising exosomes that comprise Fc receptors. In some embodiments, the exosomes in the pharmaceutical compositions described herein comprise Fc receptors including Fcgamma1 (CD64), Fcgamma2 (CD32), Fcgamma3 (CD16) or combinations thereof.
    Type: Application
    Filed: October 17, 2014
    Publication date: August 25, 2016
    Applicant: Children's Hospital Los Angeles
    Inventors: Robert C. SEEGER, Muller FABBRI, Ambrose JONG, Alan S. WAYNE
  • Publication number: 20140323553
    Abstract: The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Tolllike receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.
    Type: Application
    Filed: December 13, 2012
    Publication date: October 30, 2014
    Applicant: Ohio State Innovation Foundation
    Inventors: Carlo M. Croce, Muller Fabbri
  • Patent number: 8367632
    Abstract: Methods for restoring a desired pattern of DNA methylation, inducing re-expression of methylation-silenced tumor suppressor genes (TSGs), and/or inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof by administering an effective amount of one or more miR-29s sufficient to target one or more of DNMT3A and DNMT3B are disclosed.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: February 5, 2013
    Assignee: Ohio State University Research Foundation
    Inventors: Carlo M. Croce, Muller Fabbri
  • Publication number: 20110179501
    Abstract: Methods for restoring a desired pattern of DNA methylation, inducing re-expression of methylation-silenced tumor suppressor genes (TSGs), and/or inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof by administering an effective amount of one or more miR-29s sufficient to target one or more of DNMT3A and DNMT3B are disclosed.
    Type: Application
    Filed: July 30, 2008
    Publication date: July 21, 2011
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Carlo M. Croce, Muller Fabbri
  • Publication number: 20090270484
    Abstract: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer in a subject, by administering to the subject a polynucleotide encoding a functional WWOX gene product.
    Type: Application
    Filed: October 4, 2006
    Publication date: October 29, 2009
    Applicant: The Ohio State University Research Foundation
    Inventors: Carlo M. Croce, Muller Fabbri, Francesco Trapasso